3M Pharmaceuticals and Takeda to Collaborate on Potential Treatment for Cervical High-Risk HPV Infection and Cervical Dysplasia
3M and Takeda Pharmaceutical Company Limited announced that the two companies entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia.
The compound is currently in early stage (Phase I) clinical testing. Under the terms of this agreement, 3M and Takeda will share further costs of development. Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain Asian countries, and 3M will have exclusive commercialization rights in all other areas of the world.
The compound is part of the family of immune response modifier (IRM) molecules developed by 3M Pharmaceuticals. IRMs act in a novel way to stimulate the human body's immune system to fight virus-infected cells and tumor cells.
Other news from the department business & finance
